Replies to post #20157 on Ayala Pharmaceuticals Inc (ADXS)

[bill_y]

tx_farmer wow.."We believe that we can use our Lm Technology with an number of antigens.".doc..universally engineered adjunct therapy. great article..confirms what we suspected to be true..

" and these immunotherapies just as easily have the potential to be added to the standard of care alongside frontline treatments, too.  There’s certainly a paradigm shift coming."

as for timeline "The Cures Act is important for Advaxis in a number of ways.."

multiple partnerships coming.." we have seen strong data suggesting how our lead product candidate, axalimogene filolisbac, will work well with Merck’s KEYTRUDA® and AstraZeneca’s duvalumab."

so much more in the article..finaly getting the word out

[samk]

tx_farmer, thanks for posting this great interview!

A couple of things stand out to picture ADXS future:

"Immunotherapy will become the backbone for a multi-modality approach to treat advanced cancers. With the superior ability of immunotherapies to eliminate residual cancers following frontline treatment modalities of chemotherapy and radiation, it will be key in preventing disease progression and recurrence. With checkpoint inhibitors and therapeutic vaccines, such as axalimogene filolisbac which is being tested in phase 3 studies for advanced cervical cancer, there are significant changes coming to maintenance therapy and the adjuvant therapy setting, and these immunotherapies just as easily have the potential to be added to the standard of care alongside frontline treatments, too. There’s certainly a paradigm shift coming."

"In addition, we have seen strong data suggesting how our lead product candidate, axalimogene filolisbac, will work well with Merck’s KEYTRUDA® and AstraZeneca’s duvalumab." - now we know
that with Merck and Astra we are on the right track too...

[mpreorder]

An obscure sentence from the interview that didn't get the recognition it deserves:
Daniel O’Connor: As we move ADXS-NEO into the clinic this year, we have a few more intriguing preclinical programs which we have publicly disclosed, and several additional projects for which we are generating preclinical workups. In other words, projects in development that haven't been disclosed yet.

So we know there's a PIII for advanced cervical, we know DO's really really excited about neo, and now we know there are additional projects beyond neo. My guess is infectious disease as he alluded to in the interview.
The success of the PIII will only be the beginning if a very long and prosperous journey for shareholders.